L. Shirmohammadi, M. Ghayour-Mobarhan, M. Saberi-Karimian, M. Iranshahi, S. Tavallaie, M. Emamian, A. Sahebkar
{"title":"姜黄素对代谢综合征患者血清组织蛋白酶D的影响。","authors":"L. Shirmohammadi, M. Ghayour-Mobarhan, M. Saberi-Karimian, M. Iranshahi, S. Tavallaie, M. Emamian, A. Sahebkar","doi":"10.2174/1871529X19666190919110652","DOIUrl":null,"url":null,"abstract":"BACKGROUND/OBJECTIVE Inflammatory processes lead to increase the risk of metabolic syndrome (MetS). Cathepsin D is one of the main proinflammatory mediators. In current study, we aimed to investigate the effect of curcumin on serum cathepsin D in patients with MetS. MATERIALS AND METHODS The current study was conducted on 18-65 years old individuals with MetS according to the criteria of \"IDF\" guidelines. A total of 80 participants were randomly divided into two groups: treatment and control groups. The first group (n=40) were given 2 capsules containing 500mg of phosphatidylcholine complex of curcumin, and the other group (n=40) were given two 500mg capsules contain lactose as placebo for 6 weeks. Before (week 0) and after (week 6) the intervention, anthropometric indices and blood pressure were measured and blood samples were taken. Serum cathepsin D was measured using an abcam ELISA kit. RESULTS There were no significant differences between treatment and control groups in regard to weight, BMI, waist circumference and serum cathepsin D levels before and after the intervention. Also, there were no significant differences between pre and post-trial values of serum cathepsin D. CONCLUSION The results shows curcumin has not a significant effect on cathepsin D level in patients with MetS.","PeriodicalId":93925,"journal":{"name":"Cardiovascular & hematological disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Effect of Curcumin on Serum Cathepsin D in Patients with Metabolic Syndrome.\",\"authors\":\"L. Shirmohammadi, M. Ghayour-Mobarhan, M. Saberi-Karimian, M. Iranshahi, S. Tavallaie, M. Emamian, A. Sahebkar\",\"doi\":\"10.2174/1871529X19666190919110652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND/OBJECTIVE Inflammatory processes lead to increase the risk of metabolic syndrome (MetS). Cathepsin D is one of the main proinflammatory mediators. In current study, we aimed to investigate the effect of curcumin on serum cathepsin D in patients with MetS. MATERIALS AND METHODS The current study was conducted on 18-65 years old individuals with MetS according to the criteria of \\\"IDF\\\" guidelines. A total of 80 participants were randomly divided into two groups: treatment and control groups. The first group (n=40) were given 2 capsules containing 500mg of phosphatidylcholine complex of curcumin, and the other group (n=40) were given two 500mg capsules contain lactose as placebo for 6 weeks. Before (week 0) and after (week 6) the intervention, anthropometric indices and blood pressure were measured and blood samples were taken. Serum cathepsin D was measured using an abcam ELISA kit. RESULTS There were no significant differences between treatment and control groups in regard to weight, BMI, waist circumference and serum cathepsin D levels before and after the intervention. Also, there were no significant differences between pre and post-trial values of serum cathepsin D. CONCLUSION The results shows curcumin has not a significant effect on cathepsin D level in patients with MetS.\",\"PeriodicalId\":93925,\"journal\":{\"name\":\"Cardiovascular & hematological disorders drug targets\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular & hematological disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871529X19666190919110652\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X19666190919110652","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effect of Curcumin on Serum Cathepsin D in Patients with Metabolic Syndrome.
BACKGROUND/OBJECTIVE Inflammatory processes lead to increase the risk of metabolic syndrome (MetS). Cathepsin D is one of the main proinflammatory mediators. In current study, we aimed to investigate the effect of curcumin on serum cathepsin D in patients with MetS. MATERIALS AND METHODS The current study was conducted on 18-65 years old individuals with MetS according to the criteria of "IDF" guidelines. A total of 80 participants were randomly divided into two groups: treatment and control groups. The first group (n=40) were given 2 capsules containing 500mg of phosphatidylcholine complex of curcumin, and the other group (n=40) were given two 500mg capsules contain lactose as placebo for 6 weeks. Before (week 0) and after (week 6) the intervention, anthropometric indices and blood pressure were measured and blood samples were taken. Serum cathepsin D was measured using an abcam ELISA kit. RESULTS There were no significant differences between treatment and control groups in regard to weight, BMI, waist circumference and serum cathepsin D levels before and after the intervention. Also, there were no significant differences between pre and post-trial values of serum cathepsin D. CONCLUSION The results shows curcumin has not a significant effect on cathepsin D level in patients with MetS.